The use of intermittent enzalutamide dosing in the treatment of metastatic castrate-resistant prostate cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.6_suppl.81
Abstract: 81Background: Intermittent hormone manipulation in castrate-sensitive prostate cancer can improve quality of life whilst maintaining comparable disease outcomes with continuous scheduling. Enzaluta... read more here.
Keywords: castrate; use intermittent; intermittent enzalutamide; prostate cancer ... See more keywords